The Center for American Principles joined more than 50 conservative leaders and free-market organizations in signing a coalition letter opposing efforts to codify a Most-Favored-Nation (MFN) drug pricing model.
The letter warns that codifying MFN would effectively import foreign price controls into the U.S. healthcare system by tying American drug prices to those set by foreign governments. Many of these countries impose rigid price caps that delay patient access to innovative treatments and undermine pharmaceutical research and development. The coalition argues that adopting this model would weaken America’s global leadership in medical innovation, discourage private investment in breakthrough therapies, and ultimately harm patients who rely on timely access to lifesaving medicines.
The signatories emphasize that sustainable healthcare reform should focus on market-based solutions that promote competition, strengthen supply chains, and protect intellectual property — not government-mandated pricing schemes that replicate the shortcomings of foreign healthcare systems.